Revolution Medicines (RVMD) Capital Expenditures (2019 - 2026)

Revolution Medicines' Capital Expenditures history runs 8 years deep, the most recent figure standing at $786000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 71.78% year-over-year to $786000.0; the TTM figure through Mar 2026 stood at -$123000.0 (down 101.1% YoY), while the FY2025 annual figure was $1.9 million, down 81.8% from the prior year.
• Capital Expenditures was $786000.0 for Q1 2026 at Revolution Medicines, up from $454000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $7.9 million in Q2 2025 to a low of -$9.3 million in Q3 2025.
• Historically, Capital Expenditures has averaged $1.0 million across 5 years, with a median of $1.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures jumped 2682.47% in 2022, then plunged 364.03% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$6.5 million in 2022, then jumped by 119.66% to $1.3 million in 2023, then retreated by 4.68% to $1.2 million in 2024, then tumbled by 62.85% to $454000.0 in 2025, then jumped by 73.13% to $786000.0 in 2026.
• The last three Capital Expenditures figures came in at $786000.0 (Q1 2026), $454000.0 (Q4 2025), and -$9.3 million (Q3 2025), per Business Quant data.